+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autoimmune Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 134 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970378
The 7 major autoimmune hepatitis markets reached a value of US$ 115.3 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 156.9 Million by 2034, exhibiting a growth rate (CAGR) of 3.48% during 2023-2034.

The autoimmune hepatitis market has been comprehensively analyzed in this report titled "Autoimmune Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Autoimmune hepatitis refers to a chronic inflammatory liver disease characterized by the immune system disrupting healthy liver cells, leading to liver inflammation and potential long-term damage. The symptoms of this ailment can vary in intensity and may include fatigue, jaundice (yellowing of the skin and eyes), abdominal discomfort, loss of appetite, unexplained weight loss, etc. In some cases, individuals suffering from the illness might experience joint pain, skin rashes, or enlargement of the liver and spleen. The diagnosis of autoimmune hepatitis involves a comprehensive approach that includes a thorough medical history assessment, a physical examination, blood tests to measure liver enzyme levels, and the detection of specific autoantibodies associated with the disease. Additionally, the healthcare provider may also perform imaging studies like ultrasound or magnetic resonance imaging to determine liver damage or rule out various other hepatic conditions. Prompt diagnosis and early intervention are important in managing this disorder to prevent complications, such as cirrhosis and liver failure.

The escalating prevalence of immune-mediated syndrome, in which the body's immune system malfunctions and targets its own liver tissues, leading to progressive liver damage, is primarily driving the autoimmune hepatitis market. In addition to this, the rising demand for liver transplantation as a viable treatment alternative for end-stage disease conditions, where conventional therapies prove ineffective, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunosuppressive drugs, such as corticosteroids, azathioprine, mycophenolate mofetil, etc., to suppress the overactive immune response and reduce liver inflammation in individuals suffering from the disorder is further bolstering the market growth. Apart from this, the increasing awareness among healthcare professionals and the general population about the importance of early detection and timely management of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis techniques, owing to their various advantages, like rapid removal of harmful antibodies, faster recovery, symptom relief, etc., is also augmenting the market growth. Furthermore, the inflating application of biologics, such as anti-TNF agents and anti-CD20 monoclonal antibodies, which work by targeting certain components of the immune system in patients, is expected to drive the autoimmune hepatitis market during the forecast period.

This report provides an exhaustive analysis of the autoimmune hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for autoimmune hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the autoimmune hepatitis market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the autoimmune hepatitis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the autoimmune hepatitis market

Competitive Landscape:

This report also provides a detailed analysis of the current autoimmune hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the autoimmune hepatitis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the autoimmune hepatitis market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the autoimmune hepatitis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of autoimmune hepatitis across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of autoimmune hepatitis by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of autoimmune hepatitis by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with autoimmune hepatitis across the seven major markets?
  • What is the size of the autoimmune hepatitis patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of autoimmune hepatitis?
  • What will be the growth rate of patients across the seven major markets?

Autoimmune Hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for autoimmune hepatitis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the autoimmune hepatitis market?
  • What are the key regulatory events related to the autoimmune hepatitis market?
  • What is the structure of clinical trial landscape by status related to the autoimmune hepatitis market?
  • What is the structure of clinical trial landscape by phase related to the autoimmune hepatitis market?
  • What is the structure of clinical trial landscape by route of administration related to the autoimmune hepatitis market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

?1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Autoimmune Hepatitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Autoimmune Hepatitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Autoimmune Hepatitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Autoimmune Hepatitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Autoimmune Hepatitis - Unmet Needs10 Autoimmune Hepatitis - Key Endpoints of Treatment
11 Autoimmune Hepatitis - Marketed Products
11.1 List of Autoimmune Hepatitis Marketed Drugs Across the Top 7 Markets
11.1.1 Jayempi (Azathioprine)- Mitsubishi Tanabe
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Autoimmune Hepatitis - Pipeline Drugs
12.1 List of Autoimmune Hepatitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Zetomipzomib - Kezar Life Sciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JKB-122 - TaiwanJ Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VAY736 - Novartis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 Autoimmune Hepatitis - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Autoimmune Hepatitis - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Autoimmune Hepatitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Autoimmune Hepatitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Autoimmune Hepatitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Autoimmune Hepatitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Autoimmune Hepatitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Autoimmune Hepatitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Autoimmune Hepatitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Autoimmune Hepatitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Autoimmune Hepatitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Autoimmune Hepatitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Autoimmune Hepatitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Autoimmune Hepatitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Autoimmune Hepatitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Autoimmune Hepatitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Autoimmune Hepatitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Autoimmune Hepatitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Autoimmune Hepatitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Autoimmune Hepatitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Autoimmune Hepatitis - Access and Reimbursement Overview
16 Autoimmune Hepatitis - Recent Events and Inputs From Key Opinion Leaders
17 Autoimmune Hepatitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Autoimmune Hepatitis Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information